Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31495102 | 1.00 | MET (0.53) | METNQO2CXCR1HRH3KDM1A | |
| SCHEMBL2223511 | 0.87 | MET (0.52) | METNQO2CXCR1HRH3CHRM3 | |
| SCHEMBL22309754 | 0.86 | MET (0.58) | METNQO2CXCR1HRH3MAOA | |
| SCHEMBL31495087 | 0.85 | MET (0.57) | METNQO2CXCR1HRH3MAOA | |
| SCHEMBL12547598 | 0.85 | MET (0.57) | METNQO2CXCR1HRH3MAOA | |
| SCHEMBL1296276 | 0.85 | MET (0.57) | METNQO2CXCR1HRH3CHRM3 | |
| SCHEMBL31495099 | 0.84 | KDM1A (0.62) | KDM1AMAOB | |
| SCHEMBL23344107 | 0.84 | MET (0.54) | METNQO2CXCR1HRH3KDM1A | |
| SCHEMBL26792863 | 0.83 | MET (0.54) | METNQO2CXCR1HRH3KDM1A | |
| SCHEMBL15672716 | 0.82 | MAOA (0.52) | CXCR1HRH3KDM1AEGFRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | MET 2/4885NQO2 1984/4885CXCR1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.